OBJECTIVE: Currently, there are no reliable biomarkers for predicting therapeutic response in patients with rheumatoid arthritis (RA). The synovium may unlock critical information for determining efficacy, since a reduction in the numbers of sublining synovial macrophages remains the most reproducible biomarker. Thus, a clinically actionable method for the collection of synovial tissue, which can be analyzed using high-throughput strategies, must become a reality. This study was undertaken to assess the feasibility of utilizing synovial biopsies as a precision medicine-based approach for patients with RA. METHODS: Rheumatologists at 6 US academic sites were trained in minimally invasive ultrasound-guided synovial tissue biopsy. Biopsy specimens obtained from patients with RA and synovial tissue from patients with osteoarthritis (OA) were subjected to histologic analysis, fluorescence-activated cell sorting, and RNA sequencing (RNA-seq). An optimized protocol for digesting synovial tissue was developed to generate high-quality RNA-seq libraries from isolated macrophage populations. Associations were determined between macrophage transcriptional profiles and clinical parameters in RA patients. RESULTS: Patients with RA reported minimal adverse effects in response to synovial biopsy. Comparable RNA quality was observed from synovial tissue and isolated macrophages between patients with RA and patients with OA. Whole tissue samples from patients with RA demonstrated a high degree of transcriptional heterogeneity. In contrast, the transcriptional profile of isolated RA synovial macrophages highlighted different subpopulations of patients and identified 6 novel transcriptional modules that were associated with disease activity and therapy. CONCLUSION: Performance of synovial tissue biopsies by rheumatologists in the US is feasible and generates high-quality samples for research. Through the use of cutting-edge technologies to analyze synovial biopsy specimens in conjunction with corresponding clinical information, a precision medicine-based approach for patients with RA is attainable.
OBJECTIVE: Currently, there are no reliable biomarkers for predicting therapeutic response in patients with rheumatoid arthritis (RA). The synovium may unlock critical information for determining efficacy, since a reduction in the numbers of sublining synovial macrophages remains the most reproducible biomarker. Thus, a clinically actionable method for the collection of synovial tissue, which can be analyzed using high-throughput strategies, must become a reality. This study was undertaken to assess the feasibility of utilizing synovial biopsies as a precision medicine-based approach for patients with RA. METHODS: Rheumatologists at 6 US academic sites were trained in minimally invasive ultrasound-guided synovial tissue biopsy. Biopsy specimens obtained from patients with RA and synovial tissue from patients with osteoarthritis (OA) were subjected to histologic analysis, fluorescence-activated cell sorting, and RNA sequencing (RNA-seq). An optimized protocol for digesting synovial tissue was developed to generate high-quality RNA-seq libraries from isolated macrophage populations. Associations were determined between macrophage transcriptional profiles and clinical parameters in RA patients. RESULTS: Patients with RA reported minimal adverse effects in response to synovial biopsy. Comparable RNA quality was observed from synovial tissue and isolated macrophages between patients with RA and patients with OA. Whole tissue samples from patients with RA demonstrated a high degree of transcriptional heterogeneity. In contrast, the transcriptional profile of isolated RA synovial macrophages highlighted different subpopulations of patients and identified 6 novel transcriptional modules that were associated with disease activity and therapy. CONCLUSION: Performance of synovial tissue biopsies by rheumatologists in the US is feasible and generates high-quality samples for research. Through the use of cutting-edge technologies to analyze synovial biopsy specimens in conjunction with corresponding clinical information, a precision medicine-based approach for patients with RA is attainable.
Authors: Saedis Saevarsdottir; Helena Wallin; Maria Seddighzadeh; Sofia Ernestam; Pierre Geborek; Ingemar F Petersson; Johan Bratt; Ronald F van Vollenhoven Journal: Ann Rheum Dis Date: 2010-12-13 Impact factor: 19.103
Authors: Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green Journal: Arthritis Rheum Date: 2006-01
Authors: Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich Journal: Lancet Date: 2008-07-16 Impact factor: 79.321
Authors: Andrew Filer; Paola de Pablo; Gina Allen; Peter Nightingale; Alison Jordan; Paresh Jobanputra; Simon Bowman; Christopher D Buckley; Karim Raza Journal: Ann Rheum Dis Date: 2010-11-29 Impact factor: 19.103
Authors: Lorraine Yeo; Kai-Michael Toellner; Mike Salmon; Andrew Filer; Christopher D Buckley; Karim Raza; Dagmar Scheel-Toellner Journal: Ann Rheum Dis Date: 2011-07-08 Impact factor: 19.103
Authors: David Kuo; Jennifer Ding; Ian S Cohn; Fan Zhang; Kevin Wei; Deepak A Rao; Cristina Rozo; Upneet K Sokhi; Sara Shanaj; David J Oliver; Adriana P Echeverria; Edward F DiCarlo; Michael B Brenner; Vivian P Bykerk; Susan M Goodman; Soumya Raychaudhuri; Gunnar Rätsch; Lionel B Ivashkiv; Laura T Donlin Journal: Sci Transl Med Date: 2019-05-08 Impact factor: 17.956
Authors: Daimon P Simmons; Hung N Nguyen; Emma Gomez-Rivas; Yunju Jeong; A Helena Jonsson; Antonia F Chen; Jeffrey K Lange; George S Dyer; Philip Blazar; Brandon E Earp; Jonathan S Coblyn; Elena M Massarotti; Jeffrey A Sparks; Derrick J Todd; Deepak A Rao; Edy Y Kim; Michael B Brenner Journal: Sci Immunol Date: 2022-02-11
Authors: Laura T Donlin; Sung-Ho Park; Eugenia Giannopoulou; Aleksandra Ivovic; Kyung-Hyun Park-Min; Richard M Siegel; Lionel B Ivashkiv Journal: Nat Rev Rheumatol Date: 2019-06 Impact factor: 20.543
Authors: Frances Humby; Myles Lewis; Nandhini Ramamoorthi; Jason A Hackney; Michael R Barnes; Michele Bombardieri; A Francesca Setiadi; Stephen Kelly; Fabiola Bene; Maria DiCicco; Sudeh Riahi; Vidalba Rocher; Nora Ng; Ilias Lazarou; Rebecca Hands; Désirée van der Heijde; Robert B M Landewé; Annette van der Helm-van Mil; Alberto Cauli; Iain McInnes; Christopher Dominic Buckley; Ernest H Choy; Peter C Taylor; Michael J Townsend; Costantino Pitzalis Journal: Ann Rheum Dis Date: 2019-03-16 Impact factor: 19.103
Authors: Matthew J Wood; Adam Leckenby; Gary Reynolds; Rachel Spiering; Arthur G Pratt; Kenneth S Rankin; John D Isaacs; Muzlifah A Haniffa; Simon Milling; Catharien Mu Hilkens Journal: JCI Insight Date: 2019-01-24